EADO/WCM 2025 | Neoadjuvant approaches for cutaneous SCC
Vishal Patel, MD, FAAD, FACMS, George Washington University (GW), Washington, DC, comments on the significant impact of neoadjuvant therapy in the care of locally advanced cutaneous squamous cell carcinoma, highlighting its ability to induce a robust and durable T-cell response, leading to impressive clinical complete responses and potentially reducing the need for surgery. Dr Patel notes that long-term data shows that patients with pathological response to neoadjuvant therapy have improved relapse-free survival, and that understanding the optimal approach to de-escalating care is crucial. Dr Patel emphasizes that the next few years will focus on answering whether surgery is still necessary for all patients and identifying surrogate markers for response to guide treatment decisions. This interview took place at the 11th World Congress of Melanoma and 21st EADO Congress in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
